Replies to post #547080 on NorthWest Biotherapeutics Inc (NWBO)

[dr_lowenstein]

It is a silly argument, as Pazdur himself notes there is a trend toward more acceptance of ECAs, it s not the case yet in oncology, That and other methodological issues with the study will likely make FDA approval difficult at best